The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?

E.V. Baranova; F.W. Asselbergs; A. de Boer; A.H. Maitland

The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?

Translated title of the contribution: The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?

E.V. Baranova
, F.W. Asselbergs
, A. de Boer
, A.H. Maitland

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?
Original language	Undefined/Unknown
Pages (from-to)	841-8
Number of pages	8
Journal	Current Molecular Medicine
Volume	14
Issue number	7
Publication status	Published - 2014

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/25109798

Cite this

@article{70b7a859cba24747a895e0bb536d2b3b,

title = "The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?",

author = "E.V. Baranova and F.W. Asselbergs and \{de Boer\}, A. and A.H. Maitland",

year = "2014",

language = "Undefined/Unknown",

volume = "14",

pages = "841--8",

journal = "Current Molecular Medicine",

issn = "1566-5240",